SP CSK im. prof. K. Gibinskiego SUM
About SP CSK im. prof. K. Gibinskiego SUM
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Takeda
3
Kodiak Sciences Inc
2
Clinical Trials at SP CSK im. prof. K. Gibinskiego SUM
During the past decade, SP CSK im. prof. K. Gibinskiego SUM conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on
average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
2015-06-29
2019-01-18
Completed
771
Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis
2015-12-18
2018-08-21
Completed
383
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
2016-04-15
2023-05-06
Active, not recruiting
746
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
2020-09-25
2023-01-19
Completed
568
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
2020-09-30
2024-02-01
Active, not recruiting
459
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at SP CSK im. prof. K. Gibinskiego SUM
According to Clinical.Site data, the most researched conditions in "SP CSK im. prof. K. Gibinskiego SUM" are
"Colitis, Ulcerative" (3 trials), "Crohn's Disease" (1 trials), "Diabetic Macular Edema" (1 trials), "Macular Edema" (1 trials) and "Retinal Vein Occlusion" (1 trials). Many other conditions were trialed in "SP CSK im. prof. K. Gibinskiego SUM" in a lesser frequency.
Clinical Trials Intervention Types at SP CSK im. prof. K. Gibinskiego SUM
Most popular intervention types in "SP CSK im. prof. K. Gibinskiego SUM" are "Drug" (5 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Aflibercept" (2 trials), "KSI-301" (2 trials), "Sham Procedure" (2 trials), "Adalimumab" (1 trials) and "Adalimumab placebo" (1 trials). Other intervention names were less common.
Clinical Trials Genders at SP CSK im. prof. K. Gibinskiego SUM
The vast majority of trials in "SP CSK im. prof. K. Gibinskiego SUM" are
5 trials for "All" genders.
Clinical Trials Status at SP CSK im. prof. K. Gibinskiego SUM
Currently, there are NaN active trials in "SP CSK im. prof. K. Gibinskiego SUM".
undefined are not yet recruiting,
undefined are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 3 completed trials in SP CSK im. prof. K. Gibinskiego SUM,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in SP CSK im. prof. K. Gibinskiego SUM, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 5 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".